Arbitral award rendered in favour of Xintela in dispute with former underwriters
Lund, Sweden, 4 December 2020 -Xintela AB (publ) announces that the arbitral tribunal today has rendered an arbitral award in the dispute between Xintela and four former underwriters. The arbitral award dismisses the claim for payment brought by the underwriters against Xintela in its entirety. The arbitral award concerns the dispute that arose in connection […]
Xintela publishes interim report for the third quarter of 2020
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2020-30 Sep 2020)· Net sales amounted to TSEK 0 (3).· Loss before tax totalled TSEK 24,922 (loss: 28,081).· Loss per share* was SEK 0.43 (loss: 0.71).· At 30 September 2020, […]
Xintela receives ‘intention to grant’ decision from European Patent Office for stem cell product XSTEM
Lund, Sweden, 29 October 2020 – Xintela announced today that the European Patent Office (EPO) has issued an “Intention to grant” decision for the patent application covering the company’s stem cell product XSTEM®, consisting of integrin 10-selected mesenchymal stem cells. Using its unique marker technology and stem cell selection method, Xintela has developed a stem […]
Xintela applies for tissue establishment license
Lund, Sweden, 28 October 2020 – Xintela announces today that the company has submitted an application to the Medical Products Agency for a tissue establishment license for handling tissues and cells for manufacturing of medicinal products. In order to be allowed to conduct activities that handle human tissues and cells for the manufacture of medicinal […]
Xintela’s stem cells show promising results in preclinical ARDS study
Lund, Sweden, 26 October 2020 – Xintela announces today that the company’s selected human stem cells XSTEM® show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. ARDS is a life-threatening lung complication that may affect severely ill covid-19 patients. Xintela previously announced that XSTEM-ARDS is being evaluated […]
Xintela expands and strengthens management team
Lund, Sweden, August 19, 2020 – Xintela announces it is expanding and strengthening its management team with Peter Ekolind as COO (Chief Operating Officer) and Thomas Areschoug as CBO (Chief Business Officer). Sven Kili, who has had a combined role as COO and CMO (Chief Medical Officer), will focus on his role as CMO. “As […]
Xintela receives Notice of Allowance from USPTO for quality assurance of chondrocyte-based products
Lund, Sweden, July 29, 2020 – Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s patent application covering quality assurance of chondrocytes (XACT), which is important for the development of chondrocyte-based cell therapy products. This Notice of Allowance means that the USPTO intends to […]
Xintela granted preliminary approval from the European Patent Office for the treatment of brain tumors
Lund, Sweden, June 23, 2020 – Xintela today announces that the European Patent Office (EPO) has issued a preliminary approval (“Intention to grant”) for the company’s patent application related to antibody treatment of Glioblastoma and other tumors of the brain using the company’s target molecule integrin 101. Xintela’s patent application (publication number EP3258964) covers the […]
Xintela develops treatment for aggressive breast cancer
Lund, Sweden, June 17, 2020 – Xintela has decided that the company’s next focus in it’s oncology programme will be triple-negative breast cancer, which is an aggressive form of breast cancer that often metastasizes and has a poor prognosis. This decision was made based on the accumulated positive preclinical results using proprietary function blocking antibodies […]
Xintela granted 1 million SEK from Vinnova
Lund, Sweden, May 8, 2020 – Xintela has been granted 1 million SEK from Vinnova in the call for “ Innovations in the wake of the crisis – Restructuring of society, operations and production in the wake of the corona epidemic.”. The grant concerns the funding of a preclinical study to evaluate Xintela’s stem cells […]
